These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31609782)

  • 21. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
    Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic cooperation and crosstalk between
    Wang JQ; Jeelall YS; Humburg P; Batchelor EL; Kaya SM; Yoo HM; Goodnow CC; Horikawa K
    J Exp Med; 2017 Sep; 214(9):2759-2776. PubMed ID: 28701369
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.
    DO J; Yenwongfai LN; DO SI; Kim SW; Na K
    Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and prognostic value of
    Kirkegaard MK; Minderman M; Sjö LD; Pals ST; Eriksen PRG; Heegaard S
    Br J Ophthalmol; 2023 Apr; 107(4):576-581. PubMed ID: 34706861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic Alterations and MYD88
    Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
    Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling of primary vitreoretinal lymphoma.
    Arai A; Takase H; Yoshimori M; Yamamoto K; Mochizuki M; Miura O
    Cancer Sci; 2020 Apr; 111(4):1417-1421. PubMed ID: 32056332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.
    Hanbal AT; El-Ashwah S; Eladl AE; Shamaa S; Saleh LM
    J Egypt Natl Canc Inst; 2024 Oct; 36(1):31. PubMed ID: 39397180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
    Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
    Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of
    Schrader AMR; Jansen PM; Willemze R; Vermeer MH; Cleton-Jansen AM; Somers SF; Veelken H; van Eijk R; Kraan W; Kersten MJ; van den Brand M; Stevens WBC; de Jong D; Abdul Hamid M; Tanis BC; Posthuma EFM; Nijland M; Diepstra A; Pals ST; Cleven AHG; Vermaat JSP
    Blood; 2018 May; 131(18):2086-2089. PubMed ID: 29514783
    [No Abstract]   [Full Text] [Related]  

  • 32. MYD88
    Qin Y; Qiu T; Xie Z; Chen X; Liu P; Yang J; He X; Gui L; Zhou S; Jiang H; Zhang C; Yang S; Tang L; Shi Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8483-8494. PubMed ID: 37093346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated
    Liu Y; Ma X; Wu X; Hou X; Jin W; Fu L; Xun X; Yu Y; Shen Z
    Leuk Lymphoma; 2024 Aug; 65(8):1079-1089. PubMed ID: 38775302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
    Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
    BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
    Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence And Clinical Significance Of Oncogenic
    Chen YP; Ke LF; Lu JP; Wang JC; Zhu WF; Chen FF; Lin SF; Xu CW; Wu MJ; Chen G
    Onco Targets Ther; 2019; 12():10165-10175. PubMed ID: 32063711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
    Kraan W; van Keimpema M; Horlings HM; Schilder-Tol EJ; Oud ME; Noorduyn LA; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Leukemia; 2014 Mar; 28(3):719-20. PubMed ID: 24253023
    [No Abstract]   [Full Text] [Related]  

  • 40. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
    Kersten MJ; Kraan W; Doorduijn J; Bromberg J; Lam K; Kluin PM; van der Holt BJ; Spaargaren M; Pals ST
    Blood Cancer J; 2014 Dec; 4(12):e266. PubMed ID: 25501023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.